buy LAENNEC HUMAN online

buy LAENNEC HUMAN online

Laennec PO Placental Supplements are refined by the same methods and quality controls as JBP Laennec placenta ampoules. Two capsules has the same equivalence of placental extract as one ampule of Laennec human placenta extract.

Anti-aging and Cosmetic Effects
• Used for skin whitening and improving moisture retention
• Promotes cellular health, communication and regeneration
• Promotes regulation of the immune and hormonal systems
• Promotes extracellular matrix regeneration
• Promotes health of the circulatory system and blood components

Components of buy LAENNEC HUMAN online Extracts
• Growth factors and Cytokines: Essential aspects of the placenta that display medicinal attributes
• 18 Amino Acids: Alanine, Arginine, Aspartate, Cystine, Phenalalanine, Glutamine, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Proline, Serine, Threonine, Tryptophan, Tyrosine, Valine
• Proteins
• Carbohydrates: energy source
• Vitamins
• Nucleic Acids and Nucleobases
• Lipids and Fatty Acids
• Mucopolysaccharides: Main components of connective tissue that work to reduce inflammation
• Minerals
• Enzymes

buy LAENNEC HUMAN online has been a historical folk remedy in Oriental countries. , the hydrolysate of human placenta, which contains therapeutic compounds, has long been refined as human placental extract (HPE). , HPE has been approved for the improvement of liver function and menopausal symptoms since its importation from . , HPE has been approved and is now widely used for improvement of fatigue, skin whitening, and antiaging. Despite this popularity, the efficacy of HPE has not been sufficiently researched.

Studies using animal models have provided evidence for liver function improvement and skin whitening attributes of HPE by liver regeneration and antimelanocyte activity [1–5]. Improvements of menopausal symptoms and fatigue have been indicated in several studies, including one from our group [6, 7].

buy LAENNEC HUMAN online Initial screening included past/current medical history and a physical examination. Eligible participants were of age. Subjects with history of chronic renal disease were excluded if their plasma creatinine levels exceeded 1.5 mg/dL, if they had history of liver cirrhosis or other hemmorhogic diseases, history of any cancer, or history of taking medications such as thrombolytic agents. Forty-two subjects (20 males, 22 females) were selected. The sample size calculations were based on the assumptions of a standardized effect size of 0.90, statistical power of 95%, and a (1-sided) type I error 5%. To meet these assumptions, 42 patients were required.